CDNA on Nasdaq
CareDx, Inc
Logo: caredx.com4
Medical transplant company based in Brisbane, founded in 20001
In its 2026 annual report the company says: “CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. Our headquarters is located in Brisbane, California, and we have other primary operations in Omaha, Nebraska and Stockholm, Sweden.”7 Its shares trade on Nasdaq under the symbol CDNA.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Jan 1, 2000Founded1
Compare with CASTLE BIOSCIENCES INC, Fulgent Genetics or BillionToOne (United States), or pick any stock.
- TickerCDNA on Nasdaq1
- IndustryServices-Medical Laboratories1
- HeadquartersBrisbane1
- Websitewww.caredx.com
- Legal formDelaware corporation1
- Incorporated inDE5
- Business address8000 Marina Blvd, 4Th Floor, Brisbane, Ca 940055
- Filer categoryLarge accelerated filer5
- LEI549300NQOFKL9NON0U063
- StatusActive3
- LEI statusLapsed (not renewed)3
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States3
- Registered withDivision of Corporations, Department of State, 29824853
See how the biggest companies compare on our leaderboards
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics-based information for transplant patients. Our headquarters is located in Brisbane, California, and we have other primary operations in Omaha, Nebraska and Stockholm, Sweden.7 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Service brought in 72% of the revenue CareDx, Inc broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Service | $209.7M | $249.4M | $274.5M |
| Patient And Digital Solutions | $37.1M | $43.6M | $56.9M |
| Product | $33.5M | $40.8M | $48.4M |
Regions
United States brought in 95% of the revenue CareDx, Inc broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $265.6M | $317.7M | $359.9M |
| Outside the United States | $14.7M | $16.1M | $19.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development19¢$71.4M
- Other costs81¢$308.1M
- Income tax0¢$271.0K
Out of $379.8M in revenue.8 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Share buybacks100¢$87.8M
Out of $42.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.8
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $379.8M | $333.8M | $280.3M |
| Research and development | $71.4M | $72.5M | $82.4M |
| Sales and marketing | $102.6M | $82.0M | $84.1M |
| General and administrative | $107.6M | $125.1M | $118.8M |
| Litigation settlement expense | $5.7M | -$96.3M | $96.3M |
| Total operating expenses | $410.6M | $293.0M | $483.7M |
| (Loss) income from operations | -$30.8M | $40.8M | -$203.4M |
| Interest income, net | $9.2M | $11.8M | $11.9M |
| Other income, net | $524.0K | $329.0K | $1.4M |
| Total other income | $9.7M | $12.1M | $13.2M |
| (Loss) income before income taxes | -$21.1M | $52.9M | -$190.1M |
| Income tax expense | -$271.0K | -$310.0K | -$141.0K |
| Net (loss) income | -$21.4M | $52.5M | -$190.3M |
| Basic (in dollars per share) | -$0.40 | $1.00 | -$3.54 |
| Diluted (in dollars per share) | -$0.40 | $0.93 | -$3.54 |
| Basic (in shares) | 53.3M shares | 52.8M shares | 53.8M shares |
| Diluted (in shares) | 53.3M shares | 56.6M shares | 53.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $65.4M | $114.7M | $82.2M | |
| Marketable securities | $111.8M | $146.0M | ||
| Accounts receivable | $42.6M | $64.6M | ||
| Inventory | $26.7M | $19.5M | ||
| Prepaid and other current assets | $10.6M | $7.1M | ||
| Total current assets | $257.1M | $351.8M | ||
| Property and equipment, net | $33.0M | $33.6M | ||
| Operating lease right-of-use assets | $22.8M | $24.3M | ||
| Marketable securities, non-current | $24.2M | $0 | ||
| Intangible assets, net | $32.0M | $38.2M | ||
| Goodwill | $40.3M | $40.3M | ||
| Restricted cash | $551.0K | $585.0K | $586.0K | |
| Other assets | $3.4M | $2.2M | ||
| Total assets | $413.2M | $491.1M | ||
| Accounts payable | $10.0M | $7.7M | ||
| Accrued compensation | $38.1M | $38.3M | ||
| Accrued and other liabilities | $41.8M | $43.4M | ||
| Total current liabilities | $89.8M | $89.4M | ||
| Deferred tax liability | $181.0K | $164.0K | ||
| Contingent consideration | $161.0K | $174.0K | ||
| Operating lease liabilities, less current portion | $19.7M | $22.3M | ||
| Other liabilities | $257.0K | $645.0K | ||
| Total liabilities | $110.1M | $112.6M | ||
| Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 50,916,644 shares issued and outstanding at December 31, 2025; 54,771,203 shares issued and outstanding at December 31, 2024 | $50.0K | $51.0K | ||
| Additional paid-in capital | $1.0B | $1.0B | ||
| Accumulated other comprehensive loss | -$5.5M | -$8.6M | ||
| Accumulated deficit | -$735.4M | -$626.2M | ||
| Total stockholders equity | $303.1M | $378.4M | $261.3M | $430.9M |
| Total liabilities and stockholders equity | $413.2M | $491.1M | ||
| Common stock, shares issued (in shares) | 50.9M shares | 54.8M shares | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares outstanding (in shares) | 50.9M shares | 54.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $65.4M | $114.7M | $82.2M | |
| Marketable securities | $111.8M | $146.0M | ||
| Accounts receivable | $42.6M | $64.6M | ||
| Inventory | $26.7M | $19.5M | ||
| Prepaid and other current assets | $10.6M | $7.1M | ||
| Total current assets | $257.1M | $351.8M | ||
| Property and equipment, net | $33.0M | $33.6M | ||
| Operating lease right-of-use assets | $22.8M | $24.3M | ||
| Marketable securities, non-current | $24.2M | $0 | ||
| Intangible assets, net | $32.0M | $38.2M | ||
| Goodwill | $40.3M | $40.3M | ||
| Restricted cash | $551.0K | $585.0K | $586.0K | |
| Other assets | $3.4M | $2.2M | ||
| Total assets | $413.2M | $491.1M | ||
| Accounts payable | $10.0M | $7.7M | ||
| Accrued compensation | $38.1M | $38.3M | ||
| Accrued and other liabilities | $41.8M | $43.4M | ||
| Total current liabilities | $89.8M | $89.4M | ||
| Deferred tax liability | $181.0K | $164.0K | ||
| Contingent consideration | $161.0K | $174.0K | ||
| Operating lease liabilities, less current portion | $19.7M | $22.3M | ||
| Other liabilities | $257.0K | $645.0K | ||
| Total liabilities | $110.1M | $112.6M | ||
| Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2025 and 2024; 50,916,644 shares issued and outstanding at December 31, 2025; 54,771,203 shares issued and outstanding at December 31, 2024 | $50.0K | $51.0K | ||
| Additional paid-in capital | $1.0B | $1.0B | ||
| Accumulated other comprehensive loss | -$5.5M | -$8.6M | ||
| Accumulated deficit | -$735.4M | -$626.2M | ||
| Total stockholders equity | $303.1M | $378.4M | $261.3M | $430.9M |
| Total liabilities and stockholders equity | $413.2M | $491.1M | ||
| Common stock, shares issued (in shares) | 50.9M shares | 54.8M shares | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||
| Common stock, shares outstanding (in shares) | 50.9M shares | 54.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$21.4M | $52.5M | -$190.3M |
| Stock-based compensation | $34.9M | $66.4M | $49.1M |
| Asset impairments and write-downs | $0 | $0 | $1.0M |
| Impairment of intangible asset and associated construction in progress | $2.3M | $0 | $0 |
| Depreciation and amortization | $15.0M | $14.2M | $14.4M |
| Amortization of right-of-use assets | $5.4M | $5.6M | $5.4M |
| Realized gain on sale of long-term marketable equity securities, net | $0 | $0 | -$284.0K |
| Loss on disposal of asset | $48.0K | $91.0K | $44.0K |
| Gain on settlement of obligation and recovery of written-off investment | $0 | $0 | -$2.1M |
| Revaluation of common stock warrant liability to estimated fair value | $0 | $0 | -$10.0K |
| Revaluation of contingent consideration to estimated fair value | $703.0K | $931.0K | $2.7M |
| Amortization of premium and accretion of discount on marketable securities, net | $1.3M | $621.0K | -$4.9M |
| Accounts receivable | $22.5M | -$13.7M | $16.0M |
| Inventory | -$5.0M | -$1.0M | $54.0K |
| Prepaid and other assets | -$4.4M | $606.0K | $1.8M |
| Accounts payable | $808.0K | -$5.1M | $2.9M |
| Accrued compensation | -$845.0K | $18.7M | $2.7M |
| Accrued and other liabilities | -$3.3M | -$95.7M | $89.6M |
| Accrued royalties | $0 | $0 | -$1.6M |
| Operating lease liabilities, net | -$6.0M | -$5.9M | -$5.4M |
| Deferred taxes | $17.0K | -$187.0K | $566.0K |
| Net cash provided by (used in) operating activities | $42.0M | $38.0M | -$18.4M |
| Maturities of marketable securities | $154.7M | $166.9M | $256.0M |
| Purchases of marketable securities | -$145.9M | -$160.3M | -$201.2M |
| Purchase of corporate equity securities | $0 | -$634.0K | -$965.0K |
| Sale of corporate equity securities | $0 | $0 | $2.5M |
| Additions of capital expenditures | -$5.9M | -$6.5M | -$8.3M |
| Acquisition of intangible assets | -$675.0K | $0 | -$896.0K |
| Acquisition of business, net of cash acquired | $0 | $0 | -$6.7M |
| Net cash provided by (used in) investing activities | $2.2M | -$483.0K | $40.4M |
| Payment of contingent consideration | -$1.5M | -$5.3M | -$625.0K |
| Repurchase and retirement of common stock | -$87.8M | -$522.0K | -$27.5M |
| Proceeds from exercise of warrants | $0 | $0 | $4.0K |
| Proceeds from exercise of stock options | $5.7M | $8.9M | $120.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $2.3M | $1.4M | $1.5M |
| Taxes paid related to net share settlement of restricted stock units | -$12.1M | -$10.1M | -$3.1M |
| Net cash used in financing activities | -$93.4M | -$5.6M | -$29.6M |
| Effect of exchange rate changes on cash and cash equivalents | -$90.0K | $532.0K | -$112.0K |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$49.3M | $32.5M | -$7.7M |
| Cash paid for income taxes | $284.0K | $317.0K | $738.0K |
| Shares issued in lieu of payment | $88.0K | $174.0K | $216.0K |
| Operating lease right-of-use assets | $3.4M | $195.0K | $607.0K |
| Purchases of capital expenditures in accounts payable and accrued liabilities | $3.2M | $633.0K | $647.0K |
| Employee stock purchase plan shares included in accrued compensation | $1.1M | $975.0K | $556.0K |
| Contingent consideration | $0 | $0 | $3.5M |
No quarter-by-quarter statement was filed.
Corporate structure
CareDx, Inc sits at the top of its group. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of CareDx, Inc
- BAMCO INC /NY/ Filed SCHEDULE 13G/A on CareDx, Inc, latest Aug 14, 2026 (2 filings since Nov 14, 2025)
- GAGNON SECURITIES LLC Filed SCHEDULE 13G/A on CareDx, Inc, latest Aug 7, 2026 (6 filings since Mar 13, 2023)
- State Street Corporation Filed SCHEDULE 13G on CareDx, Inc, latest Aug 7, 2026 (5 filings since Jan 10, 2023)
- BlackRock Filed SCHEDULE 13G/A on CareDx, Inc, latest Jul 27, 2026 (6 filings since Feb 3, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on CareDx, Inc, latest Mar 26, 2026 (6 filings since Feb 9, 2022)
- ARK Investment Management LLC Filed SCHEDULE 13G/A on CareDx, Inc, latest Feb 14, 2025 (6 filings since Feb 9, 2022)
- Bellevue Asset Management (UK) Ltd. Filed SC 13G/A on CareDx, Inc, latest Nov 14, 2024 (3 filings since Feb 14, 2023)
- Amova Asset Management Americas, Inc. Filed SC 13G/A on CareDx, Inc, latest Nov 8, 2024 (2 filings since Feb 12, 2024)
- Sumitomo Mitsui Trust Group Filed SC 13G/A on CareDx, Inc, latest Nov 5, 2024 (2 filings since Feb 5, 2024)
- ArrowMark Colorado Holdings LLC Filed SC 13G/A on CareDx, Inc, latest Feb 14, 2024 (2 filings since Feb 15, 2023)
- Invesco Filed SC 13G/A on CareDx, Inc, latest Feb 8, 2023 (2 filings since Feb 9, 2022)
- ALGER ASSOCIATES INC Filed SC 13G/A on CareDx, Inc, latest Jan 10, 2023 (2 filings since Feb 14, 2022)
- CareDx, Inc Brisbane, California, United States
- CareDx Lab Solutions, Inc. Subsidiary · Delaware, United States
- CareDx Transplant Management, Inc. Subsidiary · Nebraska, United States
- The Transplant Pharmacy Subsidiary · Mississippi, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What CareDx, Inc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $33.0M8 Dec 31, 2025 | $33.6M8 Dec 31, 2024 | −1.7% |
| Operating-lease assets (leased space) | $22.8M8 Dec 31, 2025 | $24.3M8 Dec 31, 2024 | −6.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $65.4M8 Dec 31, 2025 | $114.7M8 Dec 31, 2024 | −43.0% |
| Marketable securities, current | $111.8M8 Dec 31, 2025 | $146.0M8 Dec 31, 2024 | −23.4% |
| Marketable securities, non-current | $24.2M8 Dec 31, 2025 | $08 Dec 31, 2024 |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $40.3M8 Dec 31, 2025 | $40.3M8 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $32.0M8 Dec 31, 2025 | $38.2M8 Dec 31, 2024 | −16.3% |
| Indefinite-lived intangibles (excluding goodwill) | $3.5M8 Dec 31, 2025 | $3.5M8 Dec 31, 2024 | −0.4% |
| Finite-lived intangibles, gross | $78.5M8 Dec 31, 2025 | $79.9M8 Dec 31, 2024 | −1.7% |
| Accumulated amortization | $46.0M8 Dec 31, 2025 | $40.0M8 Dec 31, 2024 | +15.0% |
| Finite-lived intangibles, net | $28.5M8 Dec 31, 2025 | $34.7M8 Dec 31, 2024 | −17.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $26.7M8 Dec 31, 2025 | $19.5M8 Dec 31, 2024 | +36.9% |
| Raw materials | $13.2M8 Dec 31, 2025 | $10.9M8 Dec 31, 2024 | +20.8% |
| Work in process | $3.7M8 Dec 31, 2025 | $3.8M8 Dec 31, 2024 | −1.4% |
| Finished goods | $9.8M8 Dec 31, 2025 | $4.8M8 Dec 31, 2024 | +103.4% |
Properties, in its own words
Location · Function · Square Footage
United States
The rest of Item 2
Brisbane, California · Corporate headquarters · 26,506
Brisbane, California · Research & development and clinical laboratories · 61,444
West Chester, Pennsylvania · Sales office and distribution · 6,336
Omaha, Nebraska · Digital solutions office · 24,984
Flowood, Mississippi · Transplant pharmacy · 4,800
Europe
Stockholm, Sweden · Research & development and product manufacturing · 24,940
Australia
Fremantle · Research & development · 5,199
We do not own any real property. We believe that our leased facilities are adequate to meet our current needs and that additional facilities are available for lease to meet future needs.
Item 2 of the 10-K filed Feb 25, 2026.7
Leadership
Who has led CareDx, Inc, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
Chief operating officer
20052010201520202025
- Chief executive officerJohn Walter Hanna Jr. Apr 25, 2024 to now17
- Chief executive officerPeter Maag Jun 3, 2015 to Oct 6, 202018
- ChairPeter Maag Nov 5, 2020 to Oct 6, 202119
- PresidentJohn Walter Hanna Jr. Apr 25, 2024 to now17
- PresidentPeter Maag Jun 3, 2015 to Oct 4, 201618
- Chief financial officerAnkur Dhingra Mar 25, 2021 to Mar 28, 202220
- Chief financial officerMichael Brian Bell Apr 25, 2017 to Nov 3, 202021
- Chief financial officerCharles Constanti Apr 14, 2016 to Feb 22, 201722
- Chief financial officerKen Ludlum Jul 16, 2014 to Jan 26, 201623
- Chief operating officerMitchell J. Nelles Jul 16, 2014 to Jul 12, 201824
Board members and other officers (27)
- Chief Commercial OfficerJessica Meng Sep 16, 2024 to now25
- OfficerAbraham Ronai Sep 9, 2022 to Sep 26, 202326
- OfficerMarcel Konrad Jan 5, 2021 to Jan 5, 202127
- Chief Business OfficerAlexander L. Johnson Jul 20, 2021 to Aug 22, 202428
- OfficerReginald Seeto Nov 27, 2018 to Oct 2, 202329
- Chief Commercial OfficerSasha King Oct 30, 2017 to Aug 11, 202230
- OfficerAnders Karlsson Apr 25, 2016 to Jan 25, 201831
- Chief Commercial OfficerTodd Whitson Apr 25, 2016 to Feb 22, 201732
- Chief Scientific OfficerJohn Joseph Sninsky Jan 14, 2015 to Jan 30, 201833
- Chief Commercial OfficerJoshua Defonzo Apr 9, 2015 to Jan 26, 201634
- OfficerPeter Maag Jul 16, 2014 to Apr 18, 201935
- Board memberSuresh Gunasekaran Oct 24, 2025 to now36
- Board memberJohn Walter Hanna Jr. Apr 25, 2024 to now17
- Board memberRichard Bryan Riggsbee Jun 17, 2024 to now37
- Board memberHannah Valantine Jul 2, 2021 to now38
- Board memberArthur A. Torres Sep 16, 2021 to now39
- Board memberReginald Seeto Nov 2, 2020 to Oct 2, 202340
- Board memberGrace Colon Jul 3, 2019 to Jun 21, 202341
- Board memberChristine Cournoyer Sep 3, 2019 to now42
- Board memberAmy Abernethy Jul 3, 2018 to Jan 23, 201943
- Board memberDouglas S. Miller Jul 18, 2016 to Apr 4, 201744
- Board memberWilliam A. Hagstrom Mar 4, 2015 to now45
- Board memberFred E. Cohen Jul 16, 2014 to now46
- Board memberGeorge Bickerstaff Jul 16, 2014 to now47
- Board memberPeter Maag Jul 16, 2014 to now35
- Board memberRalph Snyderman Jul 16, 2014 to Oct 4, 202248
- General counselJeffrey Adam Novack May 3, 2024 to now49
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- CareDx AB Sweden6
- CareDx Lab Solutions, Inc. Delaware6
- CareDx Pty Ltd. Australia6
- CareDx Transplant Management, Inc. Nebraska6
- The Transplant Pharmacy Mississippi6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
Timeline
- Sep 16, 20268-K Completed an acquisition or sale50
- Jul 30, 20268-K Results of operations; Regulation FD disclosure51
- Jul 7, 20268-K Completed an acquisition or sale; Regulation FD disclosure52
- Jun 15, 20268-K Executive or director change; Shareholder vote53
- Apr 28, 20268-K Entered a material agreement; Results of operations; Regulation FD disclosure54
- Apr 23, 20268-K Executive or director change55
- Apr 16, 20268-K Entered a material agreement; Results of operations; Regulation FD disclosure56
- Feb 25, 20268-K Results of operations; Executive or director change; Regulation FD disclosure57
- Feb 24, 20268-K Results of operations58
- Jan 12, 20268-K Results of operations59
- Dec 18, 20258-K Other events60
- Dec 15, 20258-K Bylaws or fiscal year changed61
- Apr 25, 2024New chief executive John Walter Hanna Jr. becomes CEO17
- Jun 3, 2015New chief executive Peter Maag becomes CEO18
- Jan 1, 2000Founded Founded1
Calendar
Coming up
- Oct 29, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.03 a share, on Nov 4, 2025.62
When it reported results
- Jul 30, 2026Reported quarterly or annual results51
- Apr 28, 2026Reported quarterly or annual results54
- Apr 16, 2026Reported quarterly or annual results56
- Feb 25, 2026Reported quarterly or annual results57
- Feb 24, 2026Reported quarterly or annual results58
- Jan 12, 2026Reported quarterly or annual results59
- Nov 4, 2025Reported quarterly or annual results63
- Aug 6, 2025Reported quarterly or annual results64
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
548 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 63 major events, 323 insider forms, 44 large holders, 98 other. The latest 20:
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Sep 16, 20268-K/A EDGAR
- Sep 15, 20264 EDGAR
- Sep 15, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026144 EDGAR
- Aug 12, 2026144 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 10, 2026144 EDGAR
- Aug 10, 2026144 EDGAR
- Aug 7, 2026144 EDGAR
- Aug 7, 2026SCHEDULE 13G/A EDGAR
- Aug 7, 2026SCHEDULE 13G EDGAR
- Aug 6, 20264 EDGAR
The 548 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
93 open-market trades by officers, directors and large owners since October 2021: 2 buys and 91 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Novack Jeffrey AdamSecretary and General Counsel | Sale | 2,688 | $46.26 | $124.4K | Form 4 |
| Aug 5, 2026 | Bickerstaff GeorgeDirector | Sale | 20,000 | $46.29 | $925.8K | Form 4 |
| Aug 4, 2026 | Goldberg MichaelDirector | Sale | 44,700 | $47.06 | $2.1M | Form 4 |
| Aug 4, 2026 | COURNOYER CHRISTINEDirector | Sale | 16,000 | $46.94 | $751.0K | Form 4 |
| Jul 16, 2026 | Valantine HannahDirector | Sale | 28,779 | $36.14 | $1.0M | Form 4 |
| Jul 16, 2026 | Hanna John Walter JRPresident and CEO | Sale | 118,000 | $37.78 | $4.5M | Form 4 |
| Jun 29, 2026 | Hanna John Walter JRPresident and CEO | Sale | 39,900 | $29.24 | $1.2M | Form 4 |
| Jun 26, 2026 | Hanna John Walter JRPresident and CEO | Sale | 100 | $29.00 | $2.9K | Form 4 |
| Jun 15, 2026 | Valantine HannahDirector | Sale | 12,103 | $23.11 | $279.7K | Form 4 |
| Jun 15, 2026 | Hanna John Walter JRPresident and CEO | Sale | 17,683 | $24.03 | $424.9K | Form 4 |
| Jun 11, 2026 | Hanna John Walter JRPresident and CEO | Sale | 21,998 | $24.02 | $528.4K | Form 4 |
| Jun 4, 2026 | Hanna John Walter JRPresident and CEO | Sale | 4,835 | $24.00 | $116.0K | Form 4 |
| May 15, 2026 | TORRES ARTHUR ADirector | Sale | 6,484 | $19.89 | $129.0K | Form 4 |
| May 14, 2026 | TORRES ARTHUR ADirector | Sale | 4,086 | $20.97 | $85.7K | Form 4 |
| May 5, 2026 | Novack Jeffrey AdamSecretary and General Counsel | Sale | 2,688 | $20.68 | $55.6K | Form 4 |
| Apr 16, 2026 | Hanna John Walter JRPresident and CEO | Sale | 10,282 | $21.12 | $217.2K | Form 4 |
| Feb 3, 2026 | Novack Jeffrey AdamSecretary and General Counsel | Sale | 4,441 | $20.56 | $91.3K | Form 4 |
| Jan 22, 2026 | Hanna John Walter JRPresident and CEO | Sale | 19,280 | $21.16 | $408.0K | Form 4 |
| Jan 21, 2026 | Hanna John Walter JRPresident and CEO | Sale | 200 | $21.00 | $4.2K | Form 4 |
| Jan 15, 2026 | Hanna John Walter JRPresident and CEO | Sale | 10,156 | $21.05 | $213.8K | Form 4 |
All 93 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BAMCO INC /NY/SCHEDULE 13G/A, 2 filings Nov 14, 2025 to Aug 14, 202665
- GAGNON SECURITIES LLCSCHEDULE 13G/A, 6 filings Mar 13, 2023 to Aug 7, 202666
- State Street CorporationSCHEDULE 13G, 5 filings Jan 10, 2023 to Aug 7, 202667
- BlackRockSCHEDULE 13G/A, 6 filings Feb 3, 2022 to Jul 27, 202668
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Mar 26, 202669
- ARK Investment Management LLCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Feb 14, 202570
- Bellevue Asset Management (UK) Ltd.SC 13G/A, 3 filings Feb 14, 2023 to Nov 14, 202471
- Amova Asset Management Americas, Inc.SC 13G/A, 2 filings Feb 12, 2024 to Nov 8, 202472
- Sumitomo Mitsui Trust GroupSC 13G/A, 2 filings Feb 5, 2024 to Nov 5, 202473
- ArrowMark Colorado Holdings LLCSC 13G/A, 2 filings Feb 15, 2023 to Feb 14, 202474
- InvescoSC 13G/A, 2 filings Feb 9, 2022 to Feb 8, 202375
- ALGER ASSOCIATES INCSC 13G/A, 2 filings Feb 14, 2022 to Jan 10, 202376
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | John W. HannaPresident and Chief Executive Officer | 46 | $693.3K | $7.2M77 |
| 2025 | Keith KennedyChief Operating Officer and Chief Financial Officer | 56 | $587.6K | $3.2M77 |
| 2025 | Abhishek JainFormer Chief Financial Officer | $282.1K | $2.6M77 | |
| 2025 | Jessica MengChief Commercial Officer | 51 | $485.4K | $2.6M77 |
| 2025 | Jeffrey NovackGeneral Counsel and Secretary | 43 | $361.9K | $1.2M77 |
| 2025 | Nathan SmithFormer Chief Financial Officer | $141.5K | $968.0K77 | |
| 2024 | John W. HannaPresident and Chief Executive Officer | 46 | $454.3K | $9.4M77 |
| 2024 | Keith KennedyChief Operating Officer and Chief Financial Officer | 56 | $148.2K | $4.5M77 |
| 2024 | Jessica MengChief Commercial Officer | 51 | $122.4K | $3.4M77 |
| 2024 | Abhishek JainFormer Chief Financial Officer | $411.2K | $2.8M77 | |
| 2024 | Jeffrey NovackGeneral Counsel and Secretary | 43 | $326.9K | $1.3M77 |
| 2023 | Abhishek JainFormer Chief Financial Officer | $405.0K | $3.1M77 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,814,709 | $137.2M | 0.0% | +292,613 |
| State Street Corp | 2,468,858 | $70.4M | 0.0% | −291,527 |
| Vanguard Capital Management LLC | 2,197,475 | $62.6M | 0.0% | +37,018 |
| Deerfield Management Company, L.P. | 1,997,618 | $56.9M | 0.7% | −193,382 |
| ARK Investment Management LLC | 1,953,531 | $55.7M | 0.4% | −274,025 |
| Boston Partners | 1,937,601 | $55.2M | 0.0% | +54,067 |
| Bamco Inc /ny/ | 1,937,326 | $55.2M | 0.1% | −1,399,083 |
| Gagnon Securities LLC | 1,770,735 | $50.5M | 9.7% | +8,861 |
| Chevy Chase Trust Holdings, LLC | 1,437,416 | $41.0M | 0.1% | −66,659 |
| Geode Capital Management, LLC | 1,328,037 | $37.9M | 0.0% | +73,923 |
| Ophir Asset Management Pty Ltd | 1,264,809 | $36.0M | 3.0% | +276,758 |
| Renaissance Technologies LLC | 1,242,959 | $35.4M | 0.0% | +58,561 |
| Braidwell LP | 1,220,602 | $34.8M | 1.3% | −952,544 |
| First Eagle Investment Management, LLC | 1,196,994 | $34.1M | 0.0% | +621,629 |
| Sumitomo Mitsui Trust Group, Inc. | 1,191,630 | $34.0M | 0.0% | −283,496 |
| Blue Water Life Science Advisors, LP | 1,190,000 | $33.9M | 21.4% | +255,000 |
| Amova Asset Management Americas, Inc. | 1,188,075 | $33.8M | 0.4% | −287,051 |
| Dimensional Fund Advisors LP | 1,181,077 | $33.7M | 0.0% | −280,837 |
| D. E. Shaw & Co., Inc. | 1,137,660 | $32.4M | 0.0% | +262,752 |
| Jacobs Levy Equity Management, Inc | 995,669 | $28.4M | 0.1% | +131,201 |
| Vanguard Portfolio Management LLC | 989,529 | $28.2M | 0.0% | +138,096 |
| Morgan Stanley | 774,299 | $22.1M | 0.0% | +348,950 |
| Divisadero Street Capital Management, LP | 700,938 | $20.0M | 0.5% | New |
| Goldman Sachs Group Inc | 699,993 | $19.9M | 0.0% | −33,339 |
| Portolan Capital Management, LLC | 684,805 | $19.5M | 0.7% | +344,453 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
14 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Mar 6, 2023 | Daniel S. GoldmanDemocratic, House | Sale | $1,001 - $15,000 | −410.1% | Report |
| Mar 2, 2021 | Tom MalinowskiDemocratic, House | Buy | $15,001 - $50,000 | −122.9% | Report |
| Jan 11, 2021 | Tom MalinowskiDemocratic, House | Partial sale | $1,001 - $15,000 | +124.5% | Report |
| Jan 8, 2021 | Tom MalinowskiDemocratic, House | Partial sale | $1,001 | +123.2% | Report |
| Jan 6, 2021 | Tom MalinowskiDemocratic, House | Partial sale | $15,001 - $50,000 | +118.9% | Report |
| Dec 29, 2020 | Tom MalinowskiDemocratic, House | Buy | $1,001 - $15,000 | −120.4% | Report |
| Dec 23, 2020 | Tom MalinowskiDemocratic, House | Buy | $1,001 - $15,000 | −126.2% | Report |
| Dec 7, 2020 | Tom MalinowskiDemocratic, House | Buy | $1,001 - $15,000 | −114.4% | Report |
| Nov 16, 2020 | Tom MalinowskiDemocratic, House | Buy | $1,001 - $15,000 | −96.6% | Report |
| Oct 9, 2020 | Tom MalinowskiDemocratic, House | Partial sale | $1,001 - $15,000 | +103.9% | Report |
| Jun 19, 2019 | Tom MalinowskiDemocratic, House | Sale | $1,001 - $15,000 | +102.4% | Report |
| Jun 17, 2019 | Tom MalinowskiDemocratic, House | Sale | $1,001 - $15,000 | +99.4% | Report |
| Apr 1, 2019 | Tom MalinowskiDemocratic, House | Buy | $1,001 - $15,000 | −64.6% | Report |
| Mar 11, 2019 | Tom MalinowskiDemocratic, House | Sale | $15,001 - $50,000 | +93.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How CareDx, Inc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCareDx, Inc.2
- CIK0001217234
- Employer ID (EIN)94-33168397
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company7
- Incorporated inDelaware7
- Fiscal year endsDecember 312
- Industry code (SIC)8071 Services-Medical Laboratories2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address8000 Marina Blvd, 4Th Floor, Brisbane, CA 940052
- Phone415-287-23002
- Shares outstanding51,734,223 as of Jul 27, 202615
- Public float$1.0B as of Jun 30, 20257
- AuditorDeloitte & Touche LLP, San Francisco, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting7
- On EDGAR sinceJan 31, 20032
- Filings1,399 in all: 4 (773), 8-K (162), 144 (65), SC 13G/A (53), 3 (41), 10-Q (37), 4/A (28), SC 13G (28)2
All 53 form types
S-8 (17), CORRESP (15), DEFA14A (14), UPLOAD (14), DEF 14A (13), 10-K (12), 424B5 (10), SCHEDULE 13G/A (10), EFFECT (9), CT ORDER (7), S-1/A (7), 8-K/A (6), ARS (5), S-1 (5), SC 13D/A (5), POS AM (4), PRE 14A (4), REGDEX (4), SCHEDULE 13G (4), 10-K/A (3), 10-Q/A (3), 424B3 (3), D (3), NT 10-Q (3), S-3 (3), S-3/A (3), S-3ASR (3), 424B4 (2), CB (2), REGDEX/A (2), SC 13D (2), SC TO-I/A (2), 3/A (1), 5 (1), 8-A12B (1), CERTNAS (1), D/A (1), DRS (1), DRS/A (1), FWP (1), NT 10-K (1), POSASR (1), RW (1), S-1MEF (1), SC TO-I (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Jul 30, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Jul 30, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | CDNA | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).7
Risk factors and legal proceedings
The risks CareDx, Inc names in Item 1A of its 10-K filed Feb 25, 2026: 66 risks under these headings, as written.7
- Risks Related to Our Business
- We have a history of losses, and we expect to incur net losses for the next several years.
- We receive a substantial portion of our revenues from Medicare, and the loss of, or a significant reduction in, reimbursement from Medicare would severely and adversely affect our financial performance.
- Our financial results currently are largely dependent on sales of AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare and AlloSure Lung tests and products, and we will need to generate sufficient revenues from these and other solutions and tests we develop to grow our business.
- Health insurers and other third-party payers may decide to revoke coverage of our existing tests, decide not to cover our future solutions or may provide inadequate reimbursement, which could jeopardize our commercial prospects.
- We are and could become subject to legal proceedings that could be time-consuming, result in costly litigation and settlements/judgments, require significant amounts of management attention and result in the diversion of significant operational resources, which could adversely affect our business, financial condition and results of operations.
- The development and commercialization of additional diagnostic solutions are key to our growth strategy. New test or product development involves a lengthy and complex process, and we may not be successful in our efforts to develop and commercialize additional diagnostic solutions.
- The field of diagnostic testing in transplantation is evolving and is subject to rapid technological change. If we are unable to develop solutions to keep pace with rapid medical and scientific change, our operating results could be harmed.
- If clinicians, hospital administrators, medical centers and laboratories do not adopt our diagnostic solutions, we will not achieve future sales growth.
- Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.
- Transplant centers may not adopt AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, AlloSure Lung or our other solutions due to historical practices or due to more favorable reimbursement policies associated with other means of monitoring transplants.
- If we are unable to successfully compete with established players in the clinical surveillance of the transplantation field, we may be unable to increase or sustain our revenues or achieve profitability.
The other 55 risks
- If we are unable to successfully and continually update our products on a timely basis, our ability to attract and retain customers could be impaired and our competitive position could be harmed.
- Our research and development efforts will be hindered if we are not able to acquire or contract with third parties for access to tissue and blood samples.
- If we cannot maintain existing clinical collaborations and enter into new ones, our efforts to commercialize and develop products could be delayed.
- If we are unable to successfully manage our growth and support demand for our tests, our business may suffer.
- Our past revenue growth rates may not be indicative of future growth, and we may not grow at all, and revenue may decline.
- If our laboratory facility in the United States becomes inoperable, we will be unable to perform AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare, AlloSure Lung and future testing solutions, if any, and our business will be harmed.
- Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks.
- Performance issues, service interruptions or price increases by our shipping carriers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.
- Our ability to commercialize our testing solutions that we develop is dependent on our relationships with laboratory services providers and their willingness to support our current and future solutions.
- If we seek to and are unable to raise additional capital on acceptable terms in the future, it may limit our ability to develop and commercialize new diagnostic solutions and technologies, and we may have to curtail or cease operations.
- The loss of key members of our senior management team or our inability to attract and retain highly skilled scientists, clinicians and laboratory and field personnel could adversely affect our business.
- Undetected errors or defects in our products could result in voluntary corrective actions or agency enforcement actions, including recall of our products, as well as harm our reputation, decrease market acceptance of our products and expose us to product liability or professional liability claims, which could exceed our resources.
- We rely extensively on third-party service providers. Failure of these parties to perform as expected, or interruptions in our relationship with these providers or their provision of services or supplies to us, could interfere with our ability to provide test results for our testing services business and kits for our products business.
- International expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.
- We are incorporating, and may in the future further incorporate, AI technologies into some of our internal processes. These technologies may present business, compliance and reputational risks.
- Disputes with labor unions may adversely affect our ability to operate in our Sweden facility and may impact our financial results.
- Our operating results may be adversely affected by unfavorable economic and market conditions.
- Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.
- If we use hazardous materials in a manner that causes injury, we could be liable for damages.
- Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting changes or require us to change our compensation policies.
- Risks Related to Acquisitions, Partnerships and Investments
- Intangibles, including goodwill, acquired in connection with acquisitions may subsequently be impaired and, if so, could increase our net accumulated deficit.
- Recent and future acquisitions and investments could disrupt our business, harm our financial condition and operating results, dilute your ownership of us and increase our debt or cause us to incur significant expense.
- We may not be able to achieve the anticipated strategic benefits from our acquisition of Ottr, XynManagement, TransChart, MedActionPlan, TTP, HLA Data Systems, or any other businesses or assets that we may acquire.
- Our License and Commercialization Agreement with Illumina may not result in material benefits to our business.
- Risks Related to Billing and Reimbursement
- Billing complexities associated with obtaining payment or reimbursement for our current and future solutions may negatively affect our revenue, cash flows and profitability.
- Healthcare reform measures could hinder or prevent the commercial success of AlloSure Kidney, AlloMap Heart, AlloSure Heart, HeartCare and AlloSure Lung.
- Risks Related to the Healthcare Regulatory Environment
- To operate our laboratory, we have to comply with the CLIA and federal and state laws and regulations governing clinical laboratories and laboratory-developed tests, including FDA regulations.
- If we are required to conduct additional analytical studies and clinical trials prior to marketing our solutions under development, those trials could lead to delays or a failure to obtain necessary regulatory approvals and harm our ability to be profitable.
- We are subject to numerous fraud and abuse and other laws and regulations pertaining to our business, the violation of any one of which could harm our business.
- Foreign governments may impose reimbursement standards, which may adversely affect our future profitability.
- Risks Related to Our Intellectual Property
- Our competitive position depends on maintaining intellectual property protection.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
- We may face intellectual property infringement claims that could be time-consuming and costly to defend and could result in our loss of significant rights and the assessment of treble damages.
- We may be required to take further action to maintain and protect our intellectual property rights against third parties.
- Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- If we are unable to protect or enforce our intellectual property rights effectively in all major markets, our business would be harmed.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest, and our business may be adversely affected.
- We may be subject to claims by third parties that we or our employees have wrongfully used or disclosed alleged trade secrets or misappropriated intellectual property, or claiming ownership of what we view as our own intellectual property.
- Our business is dependent on licenses from third parties.
- Risks Related to Information Technology, Cybersecurity, and Data Privacy
- Security breaches, loss of data, or other disruptions could compromise sensitive information, prevent access to critical information, expose us to liability, and adversely affect our business and our reputation.
- We are subject to changing laws, regulations, standards, and contractual obligations related to privacy, data protection and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions, fines, sanctions, private litigation, and/or adverse publicity and could negatively affect our operating results and business.
- Risks Related to Our Common Stock
- Our operating results may fluctuate, which could cause our stock price to decrease.
- The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of your investment.
- If our principal stockholders, executive officers and directors choose to act together, they may be able to control our management and operations, which may prevent us from taking actions that may be favorable to you.
- Sales of substantial amounts of our common stock in the public markets, or sales of our common stock by our executive officers and directors under Rule 10b5-1 plans, could adversely affect the market price of our common stock.
- We do not expect to pay dividends in the foreseeable future. As a result, you must rely on stock appreciation for any return on your investment.
- We may elect to repurchase shares of our common stock, which might limit our ability to pursue other growth opportunities.
- If we are unable to substantially utilize our net operating loss carryforwards, our financial results could be harmed.
- Our organizational documents and Delaware law make a takeover of our company more difficult, which may prevent certain changes in control and limit the market price of our common stock.
- Our amended and restated bylaws designate the federal district courts of the United States of America as the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
- General Risk Factors
- We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies in the United States, which may adversely affect our operating results.
- If equity research analysts do not publish research or reports about our business, or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.
- If we fail to maintain an effective system of internal controls, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
- Techniques employed by short sellers may drive down the market price of our common stock.
Legal proceedings
The information set forth in Note 8, Commitments and Contingencies, to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K under the caption “Litigation and Indemnification Obligations” is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.7
Links
- Websitewww.caredx.com1
- WikidataQ106238469
- SEC EDGARCIK 1217234
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCareDx, Inc on Wikidata
- 2SEC EDGARCareDx, Inc filings on SEC EDGAR
- 3
- 4Company websiteCareDx, Inc logo
- 5SEC EDGARCareDx, Inc filings on SEC EDGAR
- 6
- 7
- 8SEC EDGARCareDx, Inc 10-K for fiscal 2025
- 9SEC EDGARCareDx, Inc 10-K for fiscal 2019
- 10SEC EDGARCareDx, Inc 10-K for fiscal 2020
- 11SEC EDGARCareDx, Inc 10-K for fiscal 2021
- 12SEC EDGARCareDx, Inc 10-K for fiscal 2022
- 13SEC EDGARCareDx, Inc 10-K for fiscal 2019
- 14SEC EDGARCareDx, Inc 10-Q for fiscal 2026
- 15SEC EDGARCareDx, Inc 10-Q for fiscal 2026
- 16SEC EDGARCareDx, Inc 10-K for fiscal 2019
- 17
- 18SEC EDGARPeter Maag, Chief executive officer
- 19SEC EDGARPeter Maag, Chair
- 20
- 21
- 22
- 23SEC EDGARKen Ludlum, Chief financial officer
- 24
- 25
- 26SEC EDGARAbraham Ronai, Officer
- 27SEC EDGARMarcel Konrad, Officer
- 28
- 29SEC EDGARReginald Seeto, Officer
- 30SEC EDGARSasha King, Chief Commercial Officer
- 31SEC EDGARAnders Karlsson, Officer
- 32
- 33
- 34
- 35SEC EDGARPeter Maag, Officer
- 36SEC EDGARSuresh Gunasekaran, Board member
- 37SEC EDGARRichard Bryan Riggsbee, Board member
- 38SEC EDGARHannah Valantine, Board member
- 39SEC EDGARArthur A. Torres, Board member
- 40SEC EDGARReginald Seeto, Board member
- 41SEC EDGARGrace Colon, Board member
- 42SEC EDGARChristine Cournoyer, Board member
- 43SEC EDGARAmy Abernethy, Board member
- 44SEC EDGARDouglas S. Miller, Board member
- 45SEC EDGARWilliam A. Hagstrom, Board member
- 46SEC EDGARFred E. Cohen, Board member
- 47SEC EDGARGeorge Bickerstaff, Board member
- 48SEC EDGARRalph Snyderman, Board member
- 49SEC EDGARJeffrey Adam Novack, General counsel
- 50SEC EDGARCompleted an acquisition or sale
- 51
- 52
- 53
- 54
- 55SEC EDGARExecutive or director change
- 56
- 57
- 58SEC EDGARResults of operations
- 59SEC EDGARResults of operations
- 60SEC EDGAROther events
- 61SEC EDGARBylaws or fiscal year changed
- 62NasdaqNasdaq calendar
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75SEC EDGARInvesco SC 13G/A on CareDx, Inc
- 76
- 77